News
Clinical Trials Arena on MSN16h
Diakonos Oncology secures $20m for Phase II trial of glioblastoma treatmentDiakonos Oncology has closed a $20m private placement of Simple Agreements for Future Equity (SAFE) for its Phase II trial of ...
Vietnam Investment Review on MSN15h
CARsgen showcases Satri-cel breakthroughs at ASCO 2025 and in The LancetThe oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel ...
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its ...
INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no ...
Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...
A new way of thinking about Alzheimer's disease has yielded a discovery that could be the key to stopping the cognitive ...
Pharmaceutical Technology on MSN13h
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumblesAdditional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback